The fact that approximately 95 percent of the 353 public biopharmaceutical companies tracked by the BioWorld Stock Report saw their share price values fall in January emphasizes just how brutal the equity markets have been so far this year. The prevailing conditions bring back memories of the chaotic markets experienced back in 2008 during the global financial meltdown. This time around the markets have been derailed by fears of a flagging global economy and a world drowning in an oversupply of crude oil with producers unwilling to turn off the tap.